PMC:7274950 / 2325-2484
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 88 | 54-84 | Disease | denotes | agalsidase alfa and agalsidase |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T9 | 85-89 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T19 | 0-159 | Sentence | denotes | Two preparations of enzyme replacement therapy (ERT) -agalsidase alfa and agalsidase beta- with recombinant α-galactosidase was approved in Europe in 2001 [5]. |